Sarepta Doubles Market Cap After Long-Awaited Muscular Dystrophy Success
September 19, 2016 at 17:08 PM EDT
Sarepta Therapeutics is soaring Monday after receiving FDA approval for its Duchenne muscular dystrophy drug candidate eteplirsen, whose gauntlet through divisive committee meetings saw healthcare experts and distraught families.